Halozyme expects $1.86B-$1.925B 2026 revenue while raising non-GAAP EPS to $8.75-$9.05
Read original article on Breaking News on Seeking Alpha →Related news
- Genco projects Q4 2026 dividend over $1 per share as Q3 adjusted EBITDA reaches $68.1M Business Corporate
- Guardant raises FY2026 revenue guidance to $1.36B-$1.37B while targeting Shield cost per test of $200 by end of 2028 Business Corporate
- Eve outlines plan for first full transition flight by year-end while targeting certification in 2028 Technology Robotics
- Tenaris anticipates ~10% Q4 revenue growth and ~25% EBITDA margin amid partial Middle East recovery Business Corporate Global
- Globus Medical lowers 2026 revenue outlook to $3.09B while reiterating non-GAAP EPS of $4.95-$5.05 Business Corporate Global
- Akamai anticipates CIS revenue of $1.1B-$1.3B in 2027 as Anthropic deal timing shifts $30M into 2027 Business Corporate Global
-
BILL anticipates FY 2027 non-GAAP EPS of $3.99 to $4.15 as it targets ~33% non-GAAP operating margin
Business
Corporate
-
Redwire reaffirms 2026 revenue forecast of $450M-$500M as backlog reaches $619.7M
Business
Corporate